This study will compare progression-free survival between MRD-guided post-induction treatment strategy following zanubrutinib plus sonrotoclax therapy to continuous zanubrutinib as control.
Contact phone
(517) 364-2835
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Hematology
Webform